Downregulated microRNAs in the differential diagnosis of malignant pleural mesotheliomaEML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer.Inhibitor of apoptosis protein-1 promotes tumor cell survival in mesotheliomaPaxillin is a target for somatic mutations in lung cancer: implications for cell growth and invasionThe American Association for Thoracic Surgery guidelines for lung cancer screening using low-dose computed tomography scans for lung cancer survivors and other high-risk groupsActivating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemiaAsbestos exposure predicts cell cycle control gene promoter methylation in pleural mesotheliomaEpigenetic profiles distinguish pleural mesothelioma from normal pleura and predict lung asbestos burden and clinical outcomeAcute stress alters autonomic modulation during sleep in women approaching menopause.Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusionAdjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups.Differentiation of lung adenocarcinoma, pleural mesothelioma, and nonmalignant pulmonary tissues using DNA methylation profiles.Translation of microarray data into clinically relevant cancer diagnostic tests using gene expression ratios in lung cancer and mesothelioma.Minimally invasive esophagectomy: results of a prospective phase II multicenter trial-the eastern cooperative oncology group (E2202) study.A prognostic test for adenocarcinoma of the lung from gene expression profiling data.Radiofrequency ablation of thoracic lesions: part 2, initial clinical experience--technical and multidisciplinary considerations in 30 patients.Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma.Surgical techniques for multimodality treatment of malignant pleural mesothelioma: extrapleural pneumonectomy and pleurectomy/decortication.Differentially expressed alternatively spliced genes in malignant pleural mesothelioma identified using massively parallel transcriptome sequencingSecond generation sequencing of the mesothelioma tumor genome.Management of High-Throughput DNA Sequencing Projects: Alpheus.Genes associated with prognosis after surgery for malignant pleural mesothelioma promote tumor cell survival in vitro.Management of Complications After Pneumonectomy.Semi-supervised recursively partitioned mixture models for identifying cancer subtypes.Development of The American Association for Thoracic Surgery guidelines for low-dose computed tomography scans to screen for lung cancer in North America: recommendations of The American Association for Thoracic Surgery Task Force for Lung Cancer ScPrevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies.Identification of novel candidate oncogenes and tumor suppressors in malignant pleural mesothelioma using large-scale transcriptional profiling.Frequent HIN-1 promoter methylation and lack of expression in multiple human tumor types.Phase I to II study of pleurectomy/decortication and intraoperative intracavitary hyperthermic cisplatin lavage for mesothelioma.Multimodality treatment of diffuse malignant pleural mesothelioma.Vorinostat eliminates multicellular resistance of mesothelioma 3D spheroids via restoration of Noxa expressionMacroscopic complete resection: the goal of primary surgery in multimodality therapy for pleural mesothelioma.Fine-needle aspiration biopsies for gene expression ratio-based diagnostic and prognostic tests in malignant pleural mesotheliomaPreoperative pulmonary vascular morphology and its relationship to postpneumonectomy hemodynamicsValidation of genomics-based prognostic tests in malignant pleural mesothelioma.Impact of nonrigid motion correction technique on pixel-wise pharmacokinetic analysis of free-breathing pulmonary dynamic contrast-enhanced MR imagingDiffuse malignant mesothelioma of the pleural space and its management.Hyperthermic chemoperfusion for the treatment of malignant pleural mesothelioma.Section V: techniques of esophageal resection.The immunohistochemical characterization of sarcomatoid malignant mesothelioma of the pleura.
P50
Q23913270-7980FE9B-209A-4E5D-8377-F1310505B3FBQ27851440-40E7160E-9518-45FC-AFF4-8B35DC161DE0Q28206578-845EE1EF-8956-470F-AEC6-9AB6885B405EQ28263339-7B365AA5-A651-4072-83CD-971E8B50A957Q28269086-913D03E2-4893-45DC-8B9D-647B80AFC4C1Q28298677-E8D51790-35EB-47A6-9C54-754D3BAD0D27Q28385230-16ADB77A-1F93-4261-8E2C-6A824547206FQ28391055-9D10BEA4-1E8A-497F-B100-51F903EF090BQ30353455-90DBF226-0691-4D9C-9E4E-BF5B4F05EBE0Q30366235-FB9EA651-5922-4FFC-9382-4C8242FDFD53Q30438068-BA4F57B8-66A9-407A-94C6-7CAF4DB00494Q30490697-8D1EAB63-316C-433E-BCF6-CD4BC0D38A6BQ30718501-7D47CC6B-79A0-4171-941E-CDF918DCC62FQ30825480-7573ECAE-7B54-4743-8ECB-B111442D26A3Q30880591-C1781AF5-E6CC-442A-8ECF-0A99014D1FE0Q33211211-61EDDA2C-A216-4ECE-9BA1-8C57322604E7Q33371420-C1312981-FDBC-4147-8CA5-86A394DDC913Q33509927-A48EAD69-A43E-4338-A609-8459783E6351Q33521529-80B70F27-F942-4A0B-90B2-638AEE278D48Q33582141-4A15B038-A72F-4792-8DED-21B8280DC92EQ33642979-291D2A5D-29E0-4094-ADE0-4219515C5D4DQ33899105-94DD2149-B47F-4F7D-981F-36D26C39510BQ34044561-7384BE25-C983-43DB-8F57-B449FFFC88E9Q34180853-53E10CC7-C757-4928-AFBD-286FB61A445AQ34308138-E360FCDA-BADD-46A7-BC5C-2741A8FBE392Q34329871-C91C9ADE-16BD-40CF-B73A-2818B21928A9Q34343218-1C7423A8-B171-4118-8F4A-5C96E56CF1D1Q34350619-5DC56B79-B15D-47FF-86FD-AD0C1115D8CBQ34507188-9AD028C3-0241-4DF1-A241-CD4C54077E0CQ34523003-478AF8FE-3D28-469C-A659-6B7039121029Q34541123-BD6BA264-5369-4F1B-B073-4C1A7ABD4F93Q34616102-D13D6500-1ABB-43BE-B07E-822C8B831173Q34679620-951D3CD3-463A-4731-9C0A-3CE351E55B69Q34707146-8969C159-6C89-463B-BE8A-E9C38EF51EFAQ34715788-6275CAB4-E6EC-4DA2-BB69-94CB6F2E185AQ34754745-3B6E1B38-26C8-4146-826A-316860BD635AQ34775161-77361E0A-B910-492E-AA17-7D28AD6A9E7DQ34954219-D8581060-7ABE-43CD-A904-0018010B6294Q35168044-C383AF78-99DF-4643-B673-E4B0D98D4597Q35232383-B7CCAF96-FBE9-4DC2-84DF-4DE796AB67E3
P50
subject
description
médicu estauxunidense (1953–2018)
@ast
طبيب أمريكي عملَ رئيسًا لقسم ا ...... انت لوك الطبي في هيوستن، تكساس
@ar
name
David J. Sugarbaker
@ast
David J. Sugarbaker
@ca
David J. Sugarbaker
@en
David J. Sugarbaker
@es
David J. Sugarbaker
@fr
David J. Sugarbaker
@ga
David J. Sugarbaker
@nl
David J. Sugarbaker
@sl
ديفيد شوجربيكر
@ar
type
label
David J. Sugarbaker
@ast
David J. Sugarbaker
@ca
David J. Sugarbaker
@en
David J. Sugarbaker
@es
David J. Sugarbaker
@fr
David J. Sugarbaker
@ga
David J. Sugarbaker
@nl
David J. Sugarbaker
@sl
ديفيد شوجربيكر
@ar
altLabel
دايفيد جون شوجربيكر
@ar
دايفيد شوجربيكر
@ar
ديفيد جون شوجربيكر
@ar
prefLabel
David J. Sugarbaker
@ast
David J. Sugarbaker
@ca
David J. Sugarbaker
@en
David J. Sugarbaker
@es
David J. Sugarbaker
@fr
David J. Sugarbaker
@ga
David J. Sugarbaker
@nl
David J. Sugarbaker
@sl
ديفيد شوجربيكر
@ar
P1006
P1015
P214
P227
P244
P269
P1006
P1015
P106
P1207
n2011305415
P1412
P1477
David John Sugarbaker
@en
P1559
David John Sugarbaker
@en
P20
P21
P213
0000 0000 3272 3458
P214
P227
1125051108